MCID: GNT002
MIFTS: 52

Giant Cell Glioblastoma

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Giant Cell Glioblastoma

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 12 58 54 15 71
Monstrocellular Sarcoma 12 71

Characteristics:

Orphanet epidemiological data:

58
giant cell glioblastoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3074
MeSH 43 D005909
NCIt 49 C4325
SNOMED-CT 67 44529004
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0334588
Orphanet 58 ORPHA251579
UMLS 71 C0334588 C0334593

Summaries for Giant Cell Glioblastoma

Disease Ontology : 12 A glioblastoma multiforme that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary : Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to glial tumor and glioblastoma multiforme, and has symptoms including seizures and headache. An important gene associated with Giant Cell Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Class I MHC mediated antigen processing and presentation. The drugs Trioxsalen and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Related Diseases for Giant Cell Glioblastoma

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 glial tumor 31.3 PTEN IDH1
2 glioblastoma multiforme 31.1 TP53 SYP PTEN PPARG MGMT MDM2
3 neurofibromatosis, type iv, of riccardi 31.0 TP53 PTEN LZTR1
4 pleomorphic xanthoastrocytoma 31.0 TP53 SYP MGMT IDH1 GFAP BRAF
5 papilloma of choroid plexus 30.7 TP53 SYP GFAP
6 ganglioglioma 30.7 TP53 SYP GFAP BRAF
7 glioma 30.6 TP53 PTEN PPARG MDM2 IDH1 FGFR1
8 papilloma 30.6 TP53 PTEN FGFR3 EGFR
9 gemistocytic astrocytoma 30.5 TP53 PTEN MGMT IDH1 GFAP
10 grade iii astrocytoma 30.4 TP53 PTEN MGMT MDM2 IDH1 GFAP
11 fibrillary astrocytoma 30.4 TP53 PTEN MGMT IDH1 GFAP EGFR
12 hydrocephalus 30.4 TP53 SYP PTEN GFAP FGFR3 FGFR1
13 brain cancer 30.0 TP53 SYP PTEN MGMT MDM2 IDH1
14 glioma susceptibility 1 29.9 TP53 PTEN PPARG MGMT MDM2 LZTR1
15 gliosarcoma 29.3 TP53 TACC3 TACC1 SYP SEPTIN14 PTEN
16 lung meningioma 10.7 SYP CD34
17 nevus of ota 10.7 TP53 BRAF
18 fgfr-related craniosynostosis syndromes 10.7 FGFR3 FGFR1
19 papillary tumor of the pineal region 10.7 SYP BRAF
20 oligoastrocytoma 10.7 MGMT GFAP
21 glomangiosarcoma 10.7 TP53 SYP CD34
22 gastric liposarcoma 10.7 MDM2 CD34
23 third ventricle chordoid glioma 10.7 GFAP CD34
24 desmoplastic infantile ganglioglioma 10.7 SYP GFAP BRAF
25 lung combined type small cell carcinoma 10.7 SYP GFAP
26 adult brain stem glioma 10.7 MGMT IDH1
27 cerebral neuroblastoma 10.7 SYP GFAP
28 glomangiomatosis 10.7 TP53 SYP CD34
29 laryngeal neuroendocrine tumor 10.7 TP53 SYP
30 ring chromosome 7 10.7 TP53 MDM2
31 central nervous system rhabdomyosarcoma 10.7 MGMT IDH1
32 vaginal endometrial stromal sarcoma 10.7 SYP GFAP CD34
33 hyperplastic polyposis syndrome 10.7 TP53 BRAF
34 breast malignant phyllodes tumor 10.7 TP53 EGFR CD34
35 chordoid meningioma 10.7 SYP GFAP CD34
36 endobronchial leiomyoma 10.7 SYP GFAP CD34
37 childhood oligodendroglioma 10.7 MGMT IDH1 FGFR1
38 vagina sarcoma 10.7 SYP GFAP CD34
39 chiari malformation 10.7 SYP GFAP FGFR3
40 keratinizing squamous cell carcinoma 10.7 TP53 SYP EGFR
41 bile duct mucinous adenocarcinoma 10.7 TP53 SYP
42 sclerosing liposarcoma 10.7 MDM2 CD34
43 pediatric angiosarcoma 10.7 TP53 CD34
44 rhabdoid meningioma 10.7 SYP GFAP BRAF
45 extraventricular neurocytoma 10.7 SYP IDH1 GFAP
46 benign perivascular tumor 10.7 SYP CD34
47 clear cell meningioma 10.7 SYP GFAP CD34
48 deep leiomyoma 10.7 GFAP CD34
49 epithelioid sarcoma 10.7 SYP EGFR CD34
50 papillary adenofibroma 10.7 PTEN CD34

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma

Symptoms & Phenotypes for Giant Cell Glioblastoma

UMLS symptoms related to Giant Cell Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.18 EGFR
2 Decreased viability GR00173-A 10.18 AURKB
3 Decreased viability GR00221-A-1 10.18 AURKB EGFR FGFR1 FGFR3 PPARG
4 Decreased viability GR00221-A-2 10.18 AURKB FGFR1 FGFR3 PPARG
5 Decreased viability GR00221-A-3 10.18 FGFR3 PPARG
6 Decreased viability GR00221-A-4 10.18 AURKB EGFR PPARG
7 Decreased viability GR00402-S-2 10.18 AURKB EGFR FGFR1 FGFR3 PPARG
8 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10 CD34 MGMT NFKBIA TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10 NFKBIA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10 TP53
12 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10 NFKBIA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10 TP53
16 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10 NFKBIA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10 MGMT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10 CD34
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10 TP53
20 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10 MGMT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10 TP53
22 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10 MGMT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10 CD34
24 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10 NFKBIA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10 NFKBIA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10 MGMT
27 Decreased substrate adherent cell growth GR00193-A-2 9.65 AURKB
28 Decreased substrate adherent cell growth GR00193-A-3 9.65 BRAF
29 Decreased substrate adherent cell growth GR00193-A-4 9.65 AURKB BRAF FGFR1
30 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 AURKB BRAF EGFR
31 Reduced mammosphere formation GR00396-S 9.17 BRAF CD34 EGFR MDM2 POLE PPARG

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 AURKB BRAF CD34 EGFR FGFR1 FGFR3
2 growth/size/body region MP:0005378 10.4 AURKB BRAF EGFR FGFR1 FGFR3 GFAP
3 homeostasis/metabolism MP:0005376 10.4 AURKB BRAF CD34 EGFR FGFR1 FGFR3
4 immune system MP:0005387 10.36 BRAF CD34 EGFR FGFR1 FGFR3 GFAP
5 mortality/aging MP:0010768 10.36 AURKB BRAF EGFR FGFR1 FGFR3 GFAP
6 hematopoietic system MP:0005397 10.35 BRAF CD34 EGFR FGFR1 FGFR3 IDH1
7 cardiovascular system MP:0005385 10.3 AURKB BRAF EGFR FGFR1 GFAP LZTR1
8 endocrine/exocrine gland MP:0005379 10.27 BRAF EGFR FGFR1 MDM2 MGMT NFKBIA
9 integument MP:0010771 10.27 AURKB BRAF CD34 EGFR FGFR1 FGFR3
10 embryo MP:0005380 10.23 AURKB BRAF EGFR FGFR1 MDM2 PPARG
11 craniofacial MP:0005382 10.19 BRAF EGFR FGFR1 FGFR3 LZTR1 MDM2
12 digestive/alimentary MP:0005381 10.19 BRAF EGFR FGFR1 FGFR3 GFAP MDM2
13 neoplasm MP:0002006 10.18 AURKB BRAF CD34 EGFR FGFR3 MDM2
14 nervous system MP:0003631 10.11 BRAF EGFR FGFR1 FGFR3 GFAP MDM2
15 muscle MP:0005369 10.09 BRAF EGFR FGFR1 GFAP LZTR1 MDM2
16 limbs/digits/tail MP:0005371 10.08 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
17 normal MP:0002873 10.03 BRAF EGFR FGFR1 FGFR3 GFAP MDM2
18 hearing/vestibular/ear MP:0005377 10.02 BRAF EGFR FGFR1 FGFR3 PPARG TP53
19 no phenotypic analysis MP:0003012 9.92 AURKB EGFR FGFR1 FGFR3 MDM2 MGMT
20 renal/urinary system MP:0005367 9.56 BRAF EGFR FGFR1 FGFR3 MDM2 PPARG
21 pigmentation MP:0001186 9.55 BRAF EGFR MDM2 PTEN TP53
22 skeleton MP:0005390 9.36 BRAF EGFR FGFR1 FGFR3 IDH1 LZTR1

Drugs & Therapeutics for Giant Cell Glioblastoma

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 329)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Donepezil Approved Phase 3 120014-06-4 3152
3
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
8
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
9
Histamine Approved, Investigational Phase 3 51-45-6 774
10
Cyproheptadine Approved Phase 3 129-03-3 2913
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Alkylating Agents Phase 3
13 Analgesics Phase 3
14 Antimitotic Agents Phase 3
15 Photosensitizing Agents Phase 3
16 Dihematoporphyrin Ether Phase 3
17 Hematoporphyrin Derivative Phase 3
18 Ether Phase 3
19 Anesthetics Phase 3
20 Hematoporphyrins Phase 3
21 Anesthetics, General Phase 3
22 Anesthetics, Inhalation Phase 3
23 Central Nervous System Depressants Phase 3
24 Nootropic Agents Phase 3
25 Cholinergic Agents Phase 3
26 Cholinesterase Inhibitors Phase 3
27 Liver Extracts Phase 3
28 Cola Phase 3
29 Narcotics Phase 3
30 Analgesics, Opioid Phase 3
31 Adjuvants, Anesthesia Phase 3
32 Anesthetics, Intravenous Phase 3
33 Gastrointestinal Agents Phase 3
34 Neurotransmitter Agents Phase 3
35 Dopamine Uptake Inhibitors Phase 3
36 Central Nervous System Stimulants Phase 3
37 Dexmethylphenidate Hydrochloride Phase 3
38 Dopamine Agents Phase 3
39 Antipruritics Phase 3
40 Histamine H1 Antagonists Phase 3
41 Serotonin Agents Phase 3
42 Histamine Antagonists Phase 3
43
Histamine Phosphate Phase 3 51-74-1 65513
44 Serotonin Antagonists Phase 3
45 Anti-Allergic Agents Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Ethanol Approved Phase 1, Phase 2 64-17-5 702
48
acetic acid Approved Phase 2 64-19-7 176
49
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
50
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
3 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
4 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
5 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
6 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
7 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
8 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
9 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
10 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
11 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
12 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
15 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
17 Phase II Study Trial Of Tarceva In Patients With Recurrent/Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
18 A Phase I/II Trial of Conformal Radiotherapy and Hyperbaric Oxygen for Patients With Newly Diagnosed Glioblastoma Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
19 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
20 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
21 A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
22 Phase I/II Trial of Temozolomide and Carboplatin in Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
23 Phase II Trial of Bevacizumab in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme Unknown status NCT01013285 Phase 2 temozolomide
24 Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups Unknown status NCT00313521 Phase 2 thiotepa
25 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
26 A Phase 2 Study of R-(-)-Gossypol (Ascenta's AT-101) in Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
27 Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme Completed NCT00423735 Phase 2 Dasatinib
28 Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
29 Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting Completed NCT00047294 Phase 2 celecoxib;temozolomide;thalidomide
30 Open Label Phase II Study On STI571 (Glivec) Administered As A Daily Oral Treatment In Gliomas Completed NCT00039364 Phase 2 imatinib mesylate
31 A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma Completed NCT00036660 Phase 2 SarCNU
32 A Phase II Study of ZD 1839 (NSC 715055) for Patients With First Relapse Glioblastoma Multiforme Completed NCT00016991 Phase 2 gefitinib
33 A Phase II Study of CCI-779 in Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
34 A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme Completed NCT00014677 Phase 2
35 Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme Completed NCT00014300 Phase 2 glufosfamide
36 A Phase II Trial of High Dose Tamoxifen For The Treatment of Newly Diagnosed Supratentorial Glioblastoma Multiforme (GBM) Completed NCT00006388 Phase 2 tamoxifen citrate
37 A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boosts For Supratentorial Glioblastoma Multiforme Completed NCT00006386 Phase 2 carmustine
38 Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme Completed NCT00006358 Phase 2 temozolomide;thalidomide
39 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme Completed NCT00005826 Phase 2 rubitecan
40 Phase II Trial of BCNU Plus O6-Benzylguanine in the Treatment of Patients With Recurrent or Progressive Cerebral Anaplastic Gliomas Completed NCT00005081 Phase 2 O6-benzylguanine;carmustine
41 Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Patients With Glioblastoma Multiforme Completed NCT00004937 Phase 2 acridine carboxamide
42 A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in Combination With Temozolomide Following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme Completed NCT00004200 Phase 2 prinomastat;temozolomide
43 Phase II Clinical and Pharmacologic Study of Radiation Therapy and CAI (Carboxy-Amido Triazole) in Adults With Newly Diagnosed Glioblastoma Multiforme Completed NCT00004146 Phase 2 carboxyamidotriazole
44 A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma Completed NCT00004113 Phase 2 temozolomide
45 Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Completed NCT00004073 Phase 2 suramin
46 A Multi-Center, Open-Label Clinical Study to Evaluate the Safety and Performance of the Proxima GliaSite RTS, a Radiation Delivery System, in Patients With Recurrent Malignant Brain Tumors Undergoing Surgical Resection Completed NCT00003574 Phase 2
47 Phase II Treatment of Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme With Temodal Completed NCT00003464 Phase 2 temozolomide
48 A Phase II Trial of Paclitaxel and Topotecan With Filgrastim in Patients With Recurrent or Refractory Glioblastoma Multiforme or Anaplastic Astrocytoma Completed NCT00002814 Phase 2 paclitaxel;topotecan hydrochloride
49 ANALYSIS OF THE EFFICACY OF SURAMIN IN RECURRENT MALIGNANT PRIMARY BRAIN TUMORS Completed NCT00002639 Phase 2 chemotherapy;suramin
50 A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride

Search NIH Clinical Center for Giant Cell Glioblastoma

Genetic Tests for Giant Cell Glioblastoma

Anatomical Context for Giant Cell Glioblastoma

MalaCards organs/tissues related to Giant Cell Glioblastoma:

40
Brain, Breast, Lung, Thyroid, Skin, T Cells, Bone

Publications for Giant Cell Glioblastoma

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 124)
# Title Authors PMID Year
1
Genetic profile of the giant cell glioblastoma. 54 61
10068201 1999
2
p53 mutations versus EGF receptor expression in giant cell glioblastomas. 54 61
9370234 1997
3
Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 61
30861589 2019
4
Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage. 61
31655917 2019
5
Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study. 61
31464386 2019
6
Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. 61
31009783 2019
7
Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. 61
30368636 2019
8
Subgaleal and brain abscesses due to Salmonella enteritidis following craniotomy for giant cell glioblastoma multiforme: A case report and literature review. 61
31528375 2019
9
An Unusual Presentation of Spinal Giant Cell Glioblastoma in a 21-Year-Old Female. 61
31394931 2019
10
Imaging findings in the progression of a giant cell glioblastoma. 61
30128062 2018
11
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 61
30783357 2018
12
Glioblastoma in the setting of prior lower grade gliomas - insights from SEER database. 61
30279958 2018
13
Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor. 61
30443141 2018
14
Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. 61
29805603 2018
15
IDH-mutant giant cell glioblastoma: A neglected tumor variant? 61
29035191 2017
16
Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. 61
28288541 2017
17
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. 61
29114311 2017
18
Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case. 61
28261869 2017
19
Radiologic Dilemma in an Extra-Axial Petroclival Lesion: Low Grade versus High Grade. 61
28109858 2017
20
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. 61
28161760 2017
21
Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. 61
26443480 2016
22
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. 61
27253461 2016
23
Intraoperative Squash Cytologic Features of Subependymal Giant Cell Astrocytoma. 61
27013816 2016
24
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. 61
26344331 2015
25
Giant cell glioblastoma with calcification and long-term survival. 61
26960525 2015
26
A spontaneously occurring malignant pituicytoma in a male sprague dawley rat. 61
26441479 2015
27
Adult classical glioblastoma with a BRAF V600E mutation. 61
25885250 2015
28
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients. 61
25037316 2014
29
[Gliosarcoma of cerebral hemispheres: a clinicopathologic study of 10 cases]. 61
25567590 2014
30
Treatment and survival of patients harboring histological variants of glioblastoma. 61
24980627 2014
31
Cerebellar giant cell glioblastoma multiforme in an adult. 61
25002780 2014
32
Estimating the surface area of nonconvex particles from central planar sections. 61
24832486 2014
33
BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. 61
24345274 2014
34
Giant-cell glioblastoma of childhood associated with HIV-1 and JC virus coinfection. 61
23702739 2013
35
Epithelioid GBMs show a high percentage of BRAF V600E mutation. 61
23552385 2013
36
Recurrent giant cell glioblastoma with the neuroradiologic picture of multiple meningiomas. 61
22241593 2013
37
Giant cell glioblastoma in the pediatric age group: Report of two cases. 61
23772243 2013
38
Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. 61
22943956 2013
39
Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma. 61
22286149 2012
40
Giant cell glioblastoma in a child: A rare case report. 61
23293671 2012
41
Cytomorphology of giant cell glioblastoma: Report of a case and brief review of literature. 61
21319330 2012
42
Highly malignant behavior of a murine oligodendrocyte precursor cell line following transplantation into the demyelinated and nondemyelinated central nervous system. 61
22420305 2012
43
Glioblastoma multiforme in children: report of 13 cases and review of the literature. 61
21824566 2011
44
Acute tetraplegia and cardiac arrest following high cervical leptomeningeal metastasis of giant cell glioblastoma. 61
21658953 2011
45
Giant cell glioblastoma in the cerebrum of a Pembroke Welsh corgi. 61
21146179 2011
46
Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. 61
20051018 2010
47
A case of giant cell glioblastoma: a mimicker of a cerebral metastasis. 61
20973333 2010
48
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. 61
20467329 2010
49
CD34 expression in glioblastoma and giant cell glioblastoma. 61
20175958 2010
50
Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. 61
19332771 2009

Variations for Giant Cell Glioblastoma

Expression for Giant Cell Glioblastoma

Search GEO for disease gene expression data for Giant Cell Glioblastoma.

Pathways for Giant Cell Glioblastoma

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TP53 PTEN NFKBIA MDM2 FGFR3 FGFR1
2
Show member pathways
13.43 TP53 PTEN NFKBIA MDM2 FGFR3 FGFR1
3
Show member pathways
13.09 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
4
Show member pathways
13.01 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
5
Show member pathways
12.96 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
6
Show member pathways
12.83 PTEN NFKBIA FGFR3 FGFR1 EGFR BRAF
7
Show member pathways
12.75 TP53 PTEN PPARG NFKBIA MDM2 FGFR1
8 12.73 TP53 FGFR3 FGFR1 EGFR BRAF
9
Show member pathways
12.73 TP53 PTEN FGFR1 EGFR BRAF
10
Show member pathways
12.62 TP53 PTEN MDM2 FGFR1 EGFR BRAF
11
Show member pathways
12.62 TP53 PTEN NFKBIA MDM2 FGFR3 FGFR1
12
Show member pathways
12.56 TP53 PTEN MDM2 FGFR3 EGFR BRAF
13 12.53 TP53 PTEN PPARG NFKBIA MDM2 FGFR3
14 12.5 TP53 PTEN MDM2 FGFR3 EGFR
15 12.47 TP53 TACC3 MGMT MDM2 AURKB
16
Show member pathways
12.46 TP53 NFKBIA MDM2 EGFR BRAF
17
Show member pathways
12.44 TP53 PTEN FGFR3 FGFR1 EGFR BRAF
18
Show member pathways
12.38 TP53 NFKBIA MDM2 FGFR3 FGFR1 EGFR
19
Show member pathways
12.36 TP53 PTEN NFKBIA MDM2
20 12.35 TP53 NFKBIA MDM2 EGFR
21 12.27 TP53 MDM2 FGFR1 EGFR BRAF
22
Show member pathways
12.22 PTEN FGFR3 FGFR1 EGFR
23
Show member pathways
12.18 TP53 PPARG NFKBIA BRAF
24 12.1 TP53 PTEN MDM2 EGFR BRAF
25
Show member pathways
12.06 PTEN MDM2 EGFR BRAF
26
Show member pathways
12.05 TP53 PTEN MDM2 FGFR3 FGFR1 EGFR
27 12.03 TP53 PTEN MDM2 EGFR
28
Show member pathways
11.99 TP53 NFKBIA EGFR BRAF
29 11.91 TP53 PTEN MDM2 BRAF
30
Show member pathways
11.8 TP53 NFKBIA MDM2
31 11.78 TP53 PTEN MGMT MDM2 EGFR BRAF
32 11.74 SYP GFAP FGFR3 FGFR1
33 11.63 TP53 MDM2 FGFR3 EGFR BRAF
34
Show member pathways
11.57 TP53 NFKBIA MDM2
35 11.56 TP53 PTEN MDM2
36 11.48 TP53 PTEN MDM2
37 11.47 FGFR3 FGFR1 EGFR
38 11.45 TP53 NFKBIA MDM2
39 11.39 FGFR3 FGFR1 EGFR BRAF
40 11.27 TP53 PTEN IDH1 FGFR3 FGFR1 EGFR
41 10.59 TP53 TACC3 TACC1 NFKBIA MDM2 AURKB

GO Terms for Giant Cell Glioblastoma

Cellular components related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 TP53 TACC3 TACC1 SEPTIN14 PTEN PPARG

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 TP53 PTEN MDM2 CD34 BRAF
2 MAPK cascade GO:0000165 9.91 FGFR3 FGFR1 EGFR BRAF
3 heart development GO:0007507 9.91 TP53 PTEN PPARG MDM2
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 PTEN FGFR3 EGFR BRAF
5 protein autophosphorylation GO:0046777 9.78 FGFR3 FGFR1 EGFR AURKB
6 response to drug GO:0042493 9.77 TP53 PTEN PPARG MGMT MDM2
7 cellular response to drug GO:0035690 9.71 TP53 EGFR BRAF
8 peptidyl-tyrosine phosphorylation GO:0018108 9.71 FGFR3 FGFR1 EGFR BRAF
9 negative regulation of neuron projection development GO:0010977 9.7 PTEN MDM2 GFAP
10 negative regulation of apoptotic process GO:0043066 9.7 TP53 PTEN NFKBIA MGMT MDM2 EGFR
11 regulation of cell proliferation GO:0042127 9.65 TP53 NFKBIA FGFR1 EGFR BRAF
12 long-term synaptic potentiation GO:0060291 9.63 PTEN GFAP BRAF
13 mitotic spindle organization GO:0007052 9.61 TACC3 TACC1 AURKB
14 negative regulation of telomerase activity GO:0051974 9.6 TP53 PPARG
15 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.59 TP53 EGFR
16 response to caffeine GO:0031000 9.58 TP53 PPARG
17 salivary gland morphogenesis GO:0007435 9.58 FGFR1 EGFR
18 positive regulation of phospholipase activity GO:0010518 9.57 FGFR3 FGFR1
19 regulation of axon regeneration GO:0048679 9.51 PTEN BRAF
20 cellular response to UV-C GO:0071494 9.49 TP53 MDM2
21 response to organic cyclic compound GO:0014070 9.35 PTEN PPARG MGMT IDH1 EGFR
22 cellular response to actinomycin D GO:0072717 9.32 TP53 MDM2
23 cell proliferation GO:0008283 9.17 TP53 TACC3 TACC1 PTEN EGFR CD34

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.03 POLE MGMT MDM2 FGFR3 FGFR1 EGFR
2 nucleotide binding GO:0000166 9.63 POLE FGFR3 FGFR1 EGFR BRAF AURKB
3 protein self-association GO:0043621 9.58 TP53 SYP PPARG
4 protein tyrosine kinase activity GO:0004713 9.56 FGFR3 FGFR1 EGFR BRAF
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.54 FGFR3 FGFR1 EGFR
6 peroxisome proliferator activated receptor binding GO:0042975 9.46 TACC1 MDM2
7 enzyme binding GO:0019899 9.43 TP53 PTEN PPARG NFKBIA MDM2 EGFR
8 identical protein binding GO:0042802 9.4 TP53 SYP PTEN PPARG NFKBIA MDM2
9 fibroblast growth factor-activated receptor activity GO:0005007 9.32 FGFR3 FGFR1

Sources for Giant Cell Glioblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....